Shortage of Contrast for Imaging Services

Because of a global shortage of iodinated contrast material (Omnipaque) caused by temporary overseas manufacturing disruptions, ChristianaCare is taking steps to preserve supply so that it remains available for the most time-sensitive and urgent patient needs. (Learn more in our frequently asked questions.)

Omnipaque contrast is the most widely used contrast material for CT scans and radiographic examinations at ChristianaCare facilities. It is also used for cardiac imaging and interventions, and in the GI lab, Surgicenter and other settings.

The shortage is expected to last several weeks, and likely into the summer months.

Hospitals and health care organizations worldwide are managing the effects of the shortage and the impact to patient care.

ChristianaCare is making every effort to meet the needs of patients who need this product in their procedures. We are working individually with physicians to prioritize those patients with the most urgent needs.

Wherever possible, we are using alternative contrast material and limiting its use to ensure adequate supplies for time sensitive and emergent exams. It is possible that some elective procedures that use this product will need to be delayed.

ChristianaCare will continue to look for options to minimize disruptions created by the shortage, as we serve our community as expert, caring partners in health.

Learn more in our frequently asked questions (FAQs).

COVID-19: New Visitation Guidelines. Click here for what to expect at ChristianaCare during COVID-19.

ChristianaCare

Shortage of Contrast for Imaging Services

Because of a global shortage of iodinated contrast material (Omnipaque) caused by temporary overseas manufacturing disruptions, ChristianaCare is taking steps to preserve supply so that it remains available for the most time-sensitive and urgent patient needs. (Learn more in our frequently asked questions.)

Omnipaque contrast is the most widely used contrast material for CT scans and radiographic examinations at ChristianaCare facilities. It is also used for cardiac imaging and interventions, and in the GI lab, Surgicenter and other settings.

The shortage is expected to last several weeks, and likely into the summer months.

Hospitals and health care organizations worldwide are managing the effects of the shortage and the impact to patient care.

ChristianaCare is making every effort to meet the needs of patients who need this product in their procedures. We are working individually with physicians to prioritize those patients with the most urgent needs.

Wherever possible, we are using alternative contrast material and limiting its use to ensure adequate supplies for time sensitive and emergent exams. It is possible that some elective procedures that use this product will need to be delayed.

ChristianaCare will continue to look for options to minimize disruptions created by the shortage, as we serve our community as expert, caring partners in health.

Learn more in our frequently asked questions (FAQs).

COVID-19: New Visitation Guidelines. Click here for what to expect at ChristianaCare during COVID-19.

Helen F. Graham Cancer Center

What to Expect from CyberKnife Treatment

Preparing for your CyberKnife Treatment

Generally, you will have consultation appointments with both the surgeon and the radiation oncologist. The CyberKnife nurse coordinator will arrange for insurance preauthorizations and inform you of your dates for pretreatment tests. These tests may include blood work and a CT scan, MRI or PET scan.

Men receiving prostate cancer radiation therapy can benefit from this advanced protection for prostate cancer therapy with SpaceOAR (Organs at Risk) hydrogels. We are the only center in Delaware to offer this new technology.

The biodegradable spacers push the rectum away from the prostate and out of the high-dose radiation field to protect rectal cells from injury and thereby improve outcomes. The SpaceOAR gels are injected in a minimally invasive procedure, are safe to use and dissolve after treatment leaving nothing behind.

Scanning

Prior to treatment with the CyberKnife System, you will undergo imaging procedures to determine the size, shape and location of the tumor. The process begins with a standard high-resolution CT scan. For certain tumors, other imaging techniques such as MRI, angiography or PET may also be used.

Planning

Following the scanning process, image data are digitally transferred to the CyberKnife system’s treatment-planning workstation. Here, the treating physician identifies the exact size, shape and location of the tumor. A qualified clinician then uses the CyberKnife software to generate a treatment plan to provide the desired radiation dose to the identified tumor location without damaging surrounding healthy tissue. You do not need to be present during this step in the process.

Treatment delivery

On your treatment day:

  • Wear loose-fitting, comfortable clothes to the procedure. Most patients do not need to wear a hospital gown.
  • Before treatment, eat regularly and continue your usual activities.
  • Take all regularly prescribed medications before the treatment.
  • Please do not wear any jewelry to your treatment; four hours prior to treatment, please do not use any moisturizers, lotions, creams, powders, or deodorant on the area to be treated.
  • Bring a family member or friend with you on treatment day. He or she can wait in the Helen F. Graham Cancer Center’s Radiation Oncology waiting area while you are receiving your treatment.

During a CyberKnife procedure, you will lie comfortably on the treatment table, which automatically positions you for your treatment. Anesthesia is not required, as the procedure is painless and noninvasive. Your treatment generally lasts between 30 and 90 minutes.

After treatment and follow-up

There are minimal side effects from CyberKnife treatment. The most common side effect is fatigue. Most of the time, patients are able to go back to their usual activities but will need someone to drive them home immediately after treatment. Members of our CyberKnife team can help you to arrange alternate transportation plans if needed.

You will return soon after your treatment for a follow-up visit with the doctors. Several months after treatment, you will see the doctors and have follow-up scans to check your response to the treatment. Follow-up imaging, generally performed with a combination of CT, MRI or PET scanning, is usually performed in the months following treatment to assess the tumor’s response to the delivered radiation.

Cyberknife, ChristianaCare Helen F. Graham Cancer Center
4701 Ogletown-Stanton Road, Newark, DE 19713 directions
302-623-4836